Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.

Autor: Arias-Martinez A; Doctoral Program in Pharmacy, Universidad de Granada, Barrio Verxeles n°13 2°, CP 27850, Granada, Viveiro, Spain. arantxa.91.am@gmail.com., Martínez de Castro E; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Gallego J; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain., Arrazubi V; Medical Oncology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC, CB16/12/00398, Madrid, Spain., Fernández Montes A; Medical Oncology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain., Diez M; Medical Oncology Department, Hospital Universitario Vall d'Hebron, VHIO, Barcelona, Spain., Hernandez R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain., Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Vidal-Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca - IBSAL, Salamanca, Spain., Macias I; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain., Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain., Martin Richard M; Medical Oncology Department, Instituto Catalán de Oncología (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Sauri T; Medical Oncology Department, Hospital Clinic, Barcelona, Spain., Hierro C; Medical Oncology Department, Instituto Catalán de Oncología (ICO)-Badalona, Barcelona; Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Spain., Gil M; Medical Oncology Department, Hospital General Universitario de Valencia-Ciberonc CB16/12/0035, Valencia, Spain., Cerda P; Medical Oncology Department, Hospital Universitario Santa Creu y Sant Pau, Barcelona, Spain., Martínez Moreno E; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain., Martínez Lago N; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., Mérida-García AJ; Medical Oncology Department, Complejo Asistencial de Zamora, Zamora, Spain., Gómez González L; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain., García Navalón FJ; Medical Oncology Department, Hospital Universitario de Son Llatzer, Mallorca, Spain., Ruiz Martín M; Medical Oncology Department, Complejo Asistencial Universitario de Palencia, Palencia, Spain., Marín G; Medical Oncology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., López-López F; Medical Oncology Department, Hospital Universitario del Sureste, Madrid, Spain., Ruperez Blanco AB; Medical Oncology Department, Hospital Universitario de Toledo, Toledo, Spain., Fernández AF; Medical Oncology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain., Alvarez-Manceñido F; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1674-1686. Date of Electronic Publication: 2024 Feb 15.

Editorial: Environment and organization sustainability: an employee perspective.

Autor: Qalati SA; School of Business, Liaocheng University Liaocheng, Shandong, China., Fan M; School of Finance and Economics, Jiangsu University, Zhenjiang, China., Zhou J; School of Business, Nankai University, Tianjin, China., Sánchez Limón ML; Faculty of Commerce and Administration Victoria, Autonomous University of Tamaulipas, Ciudad Victoria, Mexico., Chen X; School of Computer Science and Technology, Shandong Institute of Business and Technology, Yantai, China.

Publikováno v: Frontiers in psychology [Front Psychol] 2023 Jul 28; Vol. 14, pp. 1241653. Date of Electronic Publication: 2023 Jul 28 (Print Publication: 2023).

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.

Autor: Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Foy V; Department of Medical Oncology, Christie Hospital, Manchester, UK., Raby S; Department of Medical Oncology, Christie Hospital, Manchester, UK., Carmona-Bayonas A; Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez, s/n, Murcia 30007, Spain., Macía-Rivas L; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Arrazubi V; Medical Oncology Department, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain., Cacho Lavin D; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Hernandez San Gil R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain., Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Fernández Montes A; Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain., Mirallas O; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Macias Declara I; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain., Vidal Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain., Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain., Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Pimentel P; Medical Oncology Department, Hospital General Universitario Santa Lucía, Cartagena, Spain., Martínez Lago N; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Sauri T; Medical Oncology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain., Martín Richard M; Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain., Mangas M; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain., Gil Raga M; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain., Calvo A; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Reguera P; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Granja M; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain., Martín Carnicero A; Medical Oncology Department, Hospital San Pedro, Logroño, Spain., Hernández Pérez C; Medical Oncology Department, Hospital Universitario Nuestra Señora de the Candelaria, Santa Cruz de Tenerife, Spain., Cerdá P; Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain., Gomez Gonzalez L; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain., Garcia Navalon F; Medical Oncology Department, Hospital Universitario Son Llatzer, Mallorca, Spain., Pacheco Barcia V; Medical Oncology Department, Hospital Universitario de Torrejón, Madrid, Spain., Gutierrez Abad D; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain., Ruiz Martín M; Medical Oncology Department, Hospital Universitario Rio Carrión de Zamora, Zamora, Spain., Weaver J; Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, UK., Mansoor W; Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, UK., Gallego J; Medical Oncology Department, Hospital General Universitario of Elche, Elche, Spain.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 04; Vol. 15, pp. 17588359231157641. Date of Electronic Publication: 2023 Mar 04 (Print Publication: 2023).

Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Autor: Plazas JG; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain. Electronic address: j.gallegoplazas@gmail.com., Arias-Martinez A; Pharmacy Department, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain., Lecumberri A; Medical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain., Martínez de Castro E; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain., Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Hernandez R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain., Montes AF; Medical Oncology Department, Complejo Hospitalario de Ourense, Ourense, Spain., Macias I; Medical Oncology Department, Hospital Universitario Parc Taulí, Sabadell, Spain., Pieras-Lopez A; Pharmacy Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain., Diez M; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain., Tocino RV; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca - ISBAL, Salamanca, Spain., Lago NM; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, Coruña, Spain., Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Gil M; Medical Oncology Department, Hospital General Universitario de Valencia - Ciberonc CB16/12/0035, Valencia, Spain., Pimentel P; Medical Oncology Department, Hospital Santa Lucía, Cartagena, Spain., Mangas M; Medical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain., Granja M; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain., Carnicero AM; Medical Oncology Department, Hospital San Pedro, Logroño, Spain., Pérez CH; Medical Oncology Department, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain., Gonzalez LG; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain.

Publikováno v: ESMO open [ESMO Open] 2022 Jun; Vol. 7 (3), pp. 100514. Date of Electronic Publication: 2022 Jun 14.

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

Autor: Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J, AGAMENON study group

Publikováno v: Gastric Cancer
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f3d92d4953160cc76bd58c743d53ed
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7086